Table 2.

Association between myeloid CH subtypes and eGFR.cys score after removing participants with prevalent myeloid neoplasms.

Predictor	Cases	β	CI 2.5%	CI 97.5%	P
myeloid CH	3330	−1.05	−1.54	−0.57	8.80 × 10–5
myeloid mCA	148	−3.36	−5.65	−1.07	9.11 × 10–3
myeloid genes	3241	−1.08	−1.57	−0.60	6.25 × 10–5
DNMT3A	1446	0.14	−0.59	0.87	0.73
TET2	778	−1.74	−2.74	−0.73	1.84 × 10–3
ASXL1	283	−1.59	−3.21	0.03	0.09
JAK2	92	−4.69	−7.56	−1.82	3.21 × 10–3
GNB1	86	−3.51	−6.40	−0.62	0.04
SRSF2	67	−2.42	−5.94	1.11	0.27
TP53	62	−0.01	−3.30	3.29	1.00
PPM1D	61	−5.87	−9.43	−2.31	3.08 × 10–3
SF3B1	52	−2.37	−6.27	1.52	0.32
FLT3	36	−0.65	−5.49	4.19	0.81
GNAS	33	1.89	−2.61	6.40	0.49
NF1	28	−1.03	−6.07	4.01	0.73
CBL	28	−12.14	−17.40	−6.88	3.44 × 10–5
STAG2	27	3.90	−1.37	9.16	0.23
PRPF40B	26	2.96	−2.29	8.21	0.35
CREBBP	24	−3.10	−8.49	2.30	0.34
KDM6A	22	−2.68	−8.49	3.14	0.45
BRCC3	21	−1.72	−7.70	4.27	0.66
IDH2	14	−5.56	−13.78	2.67	0.28
KMT2D	13	−3.43	−10.54	3.69	0.44

59 participants had both myeloid mutated genes and mCA.